Background: In both USA and Europe operate companies selling Direct-to-consumer
Introduction
The identification of the genetic basis of several common multifactorial disease and the perspective of the application toward a personalized medicine led, in the recent years, to the development of an increasing number of predictive genetic tests. In addition, the continuous biotechnological advancement is reducing the costs of genetic testing and is creating potential business opportunities. Indeed, in North America and in Europe, several companies have been established to sell "direct-to-consumer" genetic tests (DTC).
These tests are offered to unselected customers, usually through websites or pharmacies, and without a specific medical counselling. In the typical procedure, the customer purchases the test online, receives a kit to collect exfoliated oral cells and sends the sample back to the company. Company extracts DNA, characterizes a set of genetic markers and email the results with variable ancillary information, such as results interpretation and/or personalized advices.
Undoubtedly, DTC have potentially important advantages. Customers can have an easy access to genetic testing [1] , acquire consciousness of their disease risk and receive personalized suggestions to modify the lifestyle [2, 3] . However, these tests are proposed to healthy people without the mediation of any healthcare professional whereas all the persons undergoing a genetic test should receive a pre-and a post-test genetic counselling explaining scope, limitations and uncertainty of the results obtained. Moreover, the genetic-tests interpretation have the peculiarity to be perceived as definitive and unmodifiable, therefore, even when negative, a clear explanation of the real prediction ability of test should be provided. All these concerns are amplified in the case of complex disease where the prediction ability of these tests is largely unproven [4, 5, 6, 7] . The genetic basis of most complex diseases are, in fact, still in active state of definition only partially understood and the methods to calculate the risk for a single individual are not defined [8, 9] . Anecdotal cases suggest that different companies assessed different risk to the same individual for the same phenotype [10] .
Among others, nutrigenetic DTCs are becoming very popular. Many companies are, in fact, selling DTC nutrigenetic tests claiming to identify individuals with genetic risk to develop diseases, such as type 2 diabetes and osteoporosis, and provide them with tailored nutritional advices or a personalized diets [11] . Unfortunately, only in few cases an agreement among researchers on which diet suggest to individuals with specific genetic background has been reached.
For these reasons, the selling of DTC tests in Europe is rising several concerns among the scientific societies and the regulating bodies. The European Society of Human Genetics (ESHG) released a statement on DTC genetic testing for health related purposes that has been approved by the Società Italiana di Genetica Umana (SIGU) [12, 13] . This statement highlights several relevant issues: the need of a medical counsellings before and after each test, the transparency in the communications process, the legal age for testing; the acceptance of an informed consent, the respect for the customers' privacy.
In the present study we analyzed DNTs available in Italy, their state of the art and their abidance with the ESHG statement.
Data and methods
Three independent researchers queried a web search engine for DTNs offered to Italian population. The searched keyword was: "nutrigenetics" on Google Italia (http://www.google.it/) and the first 100 results were screened. The results included private practices and companies, we only selected those companies offering genetic tests directly to customers without a genetic counselling.
We examined, as we were the customer, the companies' websites and/or directly contacted them to collect further data. We collected information on: investigated clinical phenotypes, genes and SNPs assayed, methods and algorithms used for the risk prediction, costs of the services, conflict of interests (i.e. nutritional supplements selling), legal and ethical aspects.
We also assessed if companies provided scientific references supporting their test, how those references were obtained and how they defined the predictive value for each investigated SNP.
We considered as "output" of the DNTs the answer that the customer automatically receives after testing and not any other additional information that he/she could potentially obtain by contacting help desks or other customer services.
We also checked if other supplementary services were offered to customers by the companies, i.e. if the companies offered the chance to meet or to talk to a specialist (medical doctor, genetic counselor, dietitian) or if a tailored help desk service was provided (with professional or non-professional employees). Finally, we searched for laboratory quality certifications on companies websites.
All the data were collected from November, 2010 to May, 2011.
To assess the overlap in terms of common clinical phenotypes and genes analyzed by different companies, we used the Jaccard index (J) [14] . According to this test, two sets of items are as more similar as the J is higher. J is defined as the ratio between the items that are common to the two sets (intersection) on all the items that belong to one of the sets (union).
Defining A and B as the items of the first and second set, respectively, the J can be defined as:
To compute genes overlap between companies, we searched for unequivocal IDs in the NCBI Entrez Gene database. We did not obtain exhaustive SNP data, because the information provided by the companies were, usually, incomplete. We manually grouped the clinical phenotypes declared by companies in few categories.
To evaluate if companies met ESHG statements' criteria [12] , we collected information in a structured way. Firstly, we designed an evaluation list (Table 1) , in which each point refers to an aspect of the ESHG statement, then we collected data and compared them with the statements.
RESULTS AND DISCUSSION

DNT services
We found six DTC Italian companies offering seven different DNT (Table 2) Nutrigenetics, and Vitalybra). All DNTs collected sample by means of a buccal swab. Table 3 reports the main characteristics of the considered DNTs. We revealed a cost difference among the companies that can be accounted to the different number of genetic markers analyzed and to the differences in services offered.
Analyzed genes, SNPs and phenotypes
Companies communicated at some extent the genes analyzed for each DNT (Table 3 and   Table 4 ). However, only for four DNTs the complete list was provided, while for the three others the information were incomplete. For instance, Nutrisalus.Gen listed 19 single genes and a group of non-specified interleukin genes, while Test Nutrigene and Kriagen DNT did not specified which genes were assayed for celiac disease. The information regarding the SNPs were more incomplete (Table 3 and Table 4 We looked for genes assayed by more DNTs (Figure 1 ) and found that no gene was analyzed by all the DNTs. This would suggest that scientists and companies have still not reached an agreement on a core set of relevant genes with a nutrigenetics impact. On the contrary more than a third of genes (22 out of 60, 37%) were tested by a single DNT. Despite this little overlap, it is remarkable that the two most studied genes, LCT and MTHFR (tested by six DNTs), are among the few ones that have polymorphisms with a proven importance in nutrigenetics.
The assayed SNPs covered a wide spectrum of functional roles. Some polymorphisms were predisposing factors for multifactorial diseases, usually associated with a mild increase of disease risk. Others, such as those regarding celiac disease were susceptibility factors with a high negative predictive value [15, 16] . Finally, few ones were mendelian disease-causing mutations, as the ALDOB gene mutation for the familiar fructose intolerance [17] and the APOB gene (R3500Q mutation) for the familial defective apolipoprotein B-100 [18] To assess how companies selected genes and SNPs we evaluated if DNT companies reported reference studies and described methods used to select them (Table 3 ). Even if with a different level of accessibility, only Genoma DNT and Test Nutrigene, clearly reported the scientific studies used for the selection. No company declared how reference studies were selected. Nevertheless, authors believe that defining a-priori criteria to select reference studies would help to proceed to a non-arbitrary selection of markers avoiding selection bias.
The ESHG statement invites companies to provide accurate and accessible labelling information about genetic tests. By this point of view, the incomplete disclosure of data and procedure used by companies seems not to meet that statement.
We evaluated the clinical phenotypes considered by DNTs and checked whether there was an overlap among DNTs. It resulted that phenotypes analyzed were widely different and the most analyzed pertains to moderate hyperhomocysteinemia, primary lactose intolerance and dyslipedemia. (Table 6 ). The clinical phenotypes are in many cases diseases preventable by a modification of lifestyle. In this light, it seems that DNTs would meet customers wishes as detected by an UK survey [19] . In that study most of the potential customers declared that they would perform a DTC genetic test to reduce their risk to develop diseases by modifying their lifestyle.
Regarding the nutrigenetics, a clinical phenotype of relevance is the obesity. Although there are no direct evidences that individuals undergoing a DNT wants to lose weight and few scientific evidences supporting the utility of a genotype-specific dietary plans in losing weight [20, 21] , appear presumable that weight control could be one of the major drive for individuals undergoing these kind of tests. Nevertheless, only a few of DNT consider obesity (8%).
Finally, the Jaccard analysis showed which DNTs are more similar for assayed genes and clinical phenotypes (Table 5 ). We detected that overlap both in terms of genes and phenotypes was generally low, however, in all cases the jaccard index was higher for phenotypes than for genes. This could suggest that a relative higher level of agreement has been reached for relevant phenotype in nutrigenetics than for genes.
Nutritional recommendations
Outputs of DNTs resulted to range from a complete dietary plan to the sole list of assayed SNPs (Table 3) . G-diet Lifeplan, G-profile Nutrigenetics and Vitalybra elaborated an independent semi-quantitative risks for some diseases on the basis of the genetic test. Nutrigene' and Nutrisalus.Gen's results rely on the sole genetic data. Nevertheless, companies did not describe methods used to predict disease risk and to define the advices.
Genoma DNT and G-diet Lifeplan
Agreement to the ESHG statements
In this section we focused on the ethical and legal issues of about DNTs raised by ESGH statements. We formulated an evaluation list (Table 1) to compare the companies policy agreement to the ESHG statement. According to results of our list, none of the companies showed a full agreement with the ESHG statement ( Table 7) . We would underline that we did not purchase any DNT. We based our analysis only on information present on websites and collected by direct contacts with companies and resellers. Part of the information considered in this section, especially regarding privacy and biological sample destiny, could be potentially reported in other documentation, i.e. informed consent and contracts, only accessible to customers and therefore unavailable to us.
ESHG statement indicates pre-test and post-test genetic counselling as mandatory and
indicates as preferable that they are performed by counselors external to the company. Of the considered DNTs only five offered an help desk with the possibility to talk with a genetic counselor, a physician, or a dietitian. We believe that providing an help desk cannot be considered equivalent to a genetic counselling, however, this failure probably should be accounted more to the nature of DNTs (direct to consumer) than to the single companies strategies. Probably, the main issue raised by this type of services is the exposition of large part of asymptomatic population to genetic tests without the intermediation of a health professional. The opportunity for people to access to valuable information for lifestyle modification faces the risk that an individual can overestimate a test result indicating an increased risk or, on the contrary, feeling too reassured by one with a reduced risk.
Another important concern was the potential conflict of interest of companies offering DNTs.
None of them clearly stated that no conflict of interest exists. However, when company websites were carefully analyzed, we revealed that a potential conflict of interest may occur for at least two companies (also selling nutritional supplements). In fact, they sold DNTs and advice nutritional supplements, in one case also on the basis of the genetic test results.
Regarding personal information privacy and biological sample destiny we revealed different level of disclosure among companies. Five of them assured that personal information are treated in a confidential manner and that biological sample will be destroyed after the analysis. For the remaining two companies we could not obtain information on this regard. In All the DNTs, were available for minors. This point is in clear contrast with the ESHG statement on direct-to-consumer genetic tests [12] and with ESHG recommendations on genetic testing on asymptomatic minor [22] . According to published recommendations, testing on a minor should be performed only for diseases substantially influenced by genetic variations, for which a medical procedure is needed to prevent or reduce the burden of the disease and for which a delay until the legal age should be avoided. DNTs does not belong to the this type of genetic testing, therefore, testing on minors should be avoided.
One of limitation of the study is the possible skipping of DNTs services operating in Italy.
However, we used a procedure similar to that of a customer that is looking for DNTs on internet, the web search was repeated by three operators and the first 100 results were analyzed, probably more than those usually considered by a typical internet user. A further limitation would be that we did not purchased any DNT, therefore we did not experience the testing procedure, nor we consulted contracts, informed consents and answers. However, we were particularly interested to the pre-test phase, in order to known information provided to customers before they decide to perform a DNT.
CONCLUSION
Direct to consumers-nutrigenetic tests (DNTs) represent an important evolution toward the personalized medicine and it are expected to increase their relevance in the near future. Our study revealed that DNTs are common in Italy even if information provided by the companies are at variable extent of completeness, particularly about the genetic markers assayed and the methods used for risk calculation. Furthermore, the companies seems to agree only partially with the ESHG statements and recommendations.
DNT is one one of the instruments toward the practical application of personalized medicine, therefore, initial efforts made by companies should be considered of great interest. However, a more strict collaboration among scientists, regulatory bodies and private companies is needed to define an agreement on scientific, ethical and legal aspects of direct-to-consumer nutrigenetic testing. 
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